Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
11/2003
11/19/2003EP1362105A2 Anti-interferon-alpha antibodies
11/19/2003EP1362095A2 Post-partum mammalian placenta, its use and placental stem cells therefrom
11/19/2003EP1362046A1 Substituted pyrimidinone derivatives as ligands of integrin receptors
11/19/2003EP1362043A1 Lactone compounds as novel photoinitiators
11/19/2003EP1362034A1 Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone
11/19/2003EP1361898A2 Modulated release particles for aerosol delivery
11/19/2003EP1361892A1 Binding domain-immunoglobulin fusion proteins
11/19/2003EP1361884A2 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
11/19/2003EP1361882A1 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical
11/19/2003EP1361881A2 Steroid hormone products and methods for preparing them
11/19/2003EP1361869A2 Transdermal therapeutic system containing testosterone and method for the production thereof
11/19/2003EP1361858A2 Modulated release particles for aerosol delivery
11/19/2003EP1214076B1 Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
11/19/2003EP1179005B1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
11/19/2003EP1117628B1 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors
11/19/2003EP1060190B1 New salt forms of (2e)- 5-amino-5- methylhex-2- enoic acid n-methyl-n-((1r)-1-(n- methyl-n-((1r)-1-(methylcarbamoyl)-2- phenylethyl)carbamoyl)-2- (2-naphtyl)ethyl)amide
11/19/2003CN1456276A Medicines for treating thyroma and hydatoncus
11/19/2003CN1456275A Medicines for treating Hashimoto's thyroncus
11/19/2003CN1456274A Medicine for treating endocrine infiltrative exophthalmos
11/18/2003US6649648 Administering 1-chroman, 1-thiochroman or quinoline derivative as anticarcinogenic or antimetastasis agent
11/18/2003US6649643 Imidazol-4-ylmehanols and their use as inhibitors of steroid C17-20 lyase
11/18/2003US6649640 Isoxazole compositions useful as inhibitors of ERK
11/18/2003US6649622 Treating diabetes, especially Type II diabetes
11/18/2003US6649172 5-(p-carboxybenzyloxy)-2-oxybenzaldehyde derivatives; vaccine adjuvants
11/18/2003US6649161 Administering neurotoxin
11/18/2003CA2264155C N6 heterocyclic substituted adenosine derivatives
11/14/2003CA2428516A1 Slowly digestible starch product
11/14/2003CA2428514A1 Resistant starch prepared by isoamylase debranching of low amylose starch
11/13/2003WO2003093292A1 17α-FLUOROALKYL-11β-BENZALDOXIME-STEROIDS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING SAID STEROIDS AND THE USE THEREOF IN THE PRODUCTION OF MEDICAMENTS
11/13/2003WO2003093234A1 Melanocortin receptor ligands
11/13/2003WO2003092790A2 Methods for increasing the therapeutic response to electroconvulsive therapy ('ect')
11/13/2003WO2003092725A1 Method for control of depression using c terminal growth hormone (gh) fragment
11/13/2003WO2003092722A1 7-HYDROXY-16α-FLUORO-5-ANDROSTEN-17-ONES AND 7-HYDROXY-16α-FLUORO-5-ANDROSTAN-17-ONES AND DERIVATIVES THEREOF
11/13/2003WO2003092699A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
11/13/2003WO2003092605A2 Protease inhibitors
11/13/2003WO2003092588A2 4-azasteroid derivatives as androgen receptor modulators
11/13/2003WO2003092585A2 Controlled release compositions of estradiol metabolites
11/13/2003WO2003092578A2 Further syntheses of cyproterone acetate
11/13/2003WO2003029200A3 Compounds useful as reversible inhibitors of cysteine proteases
11/13/2003WO2003018134A3 Bioadhesive compositions and methods for enhanced mucosal drug absorption
11/13/2003WO2003012111A3 Conjugates for the modulation of immune responses
11/13/2003WO2002099115A3 Nucleic acid-associated proteins
11/13/2003WO2002092831A3 Method for identifying ligands for g protein coupled receptors
11/13/2003WO2002057226A8 68730 and 69112 protein kinase molecules and uses therefor
11/13/2003WO2002040020A9 Novel use of certain insulin sensitizers or ppar-gamma agonists
11/13/2003US20030212273 Pyrrolo [2,3-D] pyrimidine compounds
11/13/2003US20030212081 Bicyclic heteroaromatic compounds useful as LH agonists
11/13/2003US20030212073 Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
11/13/2003US20030212020 Antisense modulation of macrophage migration inhibitory factor expression
11/13/2003US20030211986 Protein a compositions and methods of use
11/13/2003US20030211608 Antisense modulation of glycogen synthase kinase 3 beta expression
11/13/2003US20030211577 Novel G protein-coupled receptor, GAVE7
11/13/2003US20030211513 Intracellular signaling proteins
11/13/2003CA2484963A1 7-hydroxy-16a-fluoro-5-androsten-17-ones and 7-hydroxy-16a-fluoro-5-androstan-17-ones and derivatives thereof
11/13/2003CA2484551A1 Smart pro-drugs of serine protease inhibitors
11/13/2003CA2484396A1 Method for control of depression using c terminal growth hormone (gh) fragment
11/13/2003CA2484173A1 4-azasteroid derivatives as androgen receptor modulators
11/13/2003CA2483846A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
11/13/2003CA2483787A1 Melanocortin receptor ligands
11/13/2003CA2482997A1 Further syntheses of cyproterone acetate
11/12/2003EP1361205A1 Compounds with hydroxycarbonyl-halogenalkyl side chains
11/12/2003EP1360964A1 Use of galanin-like peptide
11/12/2003EP1360304A2 Enzymes
11/12/2003EP1360295A2 Molecules for desease detection and treatment
11/12/2003EP1360279A2 Novel form of the phgpx protein as a diagnostic marker for male infertility
11/12/2003EP1360178A2 Novel heterocyclic analogs of diphenylethylene compounds
11/12/2003EP1360169A2 Succinate salt of o-desmethyl-venlafaxine
11/12/2003EP1359931A1 Prevention of diabetes by administration of gnrh antagonists
11/12/2003EP1359916A1 Imidazolyl derivatives as corticotropin releasing factor inhibitors
11/12/2003EP1359907A2 Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors
11/12/2003EP1255557B1 Stable, nasally, orally or sublingually applicable pharmaceutical preparation containing desmopressin
11/12/2003EP1229909B1 Transdermal delivery of lasofoxifene
11/12/2003EP1137400B1 Compositions containing a peptide and polylactic-glycolic acid suitable for preparing subcutaneous implants with an extended release period toff, verfahren zu seiner herstellung und anlage zur durchfuhrung des verfahrens
11/12/2003EP0991618B1 Selective thyroid hormone analogs
11/12/2003CN1455691A Pharmaceutical compositions
11/12/2003CN1455681A Contraception process and administration for same
11/12/2003CN1127511C Inhibitors of interleukin-1 ÔÇ£betaÔÇØ converting enzyme
11/12/2003CN1127488C Compouds with growth hormone releasing properties
11/12/2003CN1127484C Substituted pyrazolyl benzene sulfone amides compounds for curing inflammation
11/11/2003US6646004 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
11/11/2003US6645998 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
11/11/2003US6645995 Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
11/11/2003US6645974 Androgen receptor modulators and methods for use thereof
11/11/2003US6645951 Benzopyran or thiobenzopyran derivatives
11/11/2003CA2290332C Optically pure androgen mediator
11/06/2003WO2003091432A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
11/06/2003WO2003091282A1 Histamine receptor h3 ordinary activity mutant and utilization thereof
11/06/2003WO2003091225A1 Substituted pyrazine derivatives
11/06/2003WO2003090784A1 Treatment of metabolic syndrome
11/06/2003WO2003090754A1 Use of dhea for treatment of female hypopituitarism
11/06/2003WO2003090748A1 Use of compounds having ccr antagonism
11/06/2003WO2003090714A1 Method for the production of crystals, crystals obtained by said method, and use thereof in pharmaceutical formulations
11/06/2003WO2003090672A2 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
11/06/2003WO2003079981A3 Bioadhesive drug delivery system
11/06/2003WO2003061557A3 Levothyroxine pharmaceutical compositions, methods of making and methods of administration
11/06/2003WO2003057166A3 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003WO2003035626A3 Azole derivatives and pharmaceutical compositions containing them
11/06/2003WO2003031939A3 Protein modification and maintenance molecules
11/06/2003WO2003028624A3 Levothyroxine compositions and methods
11/06/2003WO2003027263A3 Proteins associated with cell growth, differentiation, and death
1 ... 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 ... 290